Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA3 | P07451 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA6 | P23280 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 8/20 | 0.33 |
| ▸ | TP53 | P04637 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789746 | 0.83 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL21313417 | 0.83 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3789749 | 0.83 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8353244 | 0.83 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1880935 | 0.83 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1878246 | 0.83 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13911898 | 0.82 | LMNA (0.71) | LMNACA12CA1CA2CA3 | |
| SCHEMBL16885529 | 0.80 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL22151991 | 0.79 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4496231 | 0.79 | ALDH1A1 (0.46) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034958-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UOB Pharma, S.A. (BE) | 2011-10-11 | — | — | US | disclosed |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2010-09-02 | — | — | US | disclosed |
| US-7563912-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1419144-B1 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB PHARMA SA (BE) | 2008-10-08 | — | — | EP | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-7122682-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB, S.A. (BE) | 2006-10-17 | — | — | US | disclosed |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2004-10-14 | — | — | US | disclosed |
| EP-1419144-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014080-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | LMNA 3694/4885CA12 4426/4885CA1 2098/4885 |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2C19, CYP2C9, TPMT | LMNA 3589/4885CA12 2116/4885CA1 1011/4885 |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | TPMT, CYP2C9, OTC | LMNA 2489/4885CA12 2370/4885CA1 1525/4885 |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2D6, OTC, CYP2B6 | LMNA 2327/4885CA12 2417/4885CA1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.